IBDEI3J5 ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,2789,0)
;;=SUBSTANCE DISORDERS^35^256
;;^UTILITY(U,$J,358.4,2790,0)
;;=VARICOSE VEINS^36^256
;;^UTILITY(U,$J,358.4,2791,0)
;;=WOMEN'S HEALTH^37^256
;;^UTILITY(U,$J,358.4,2792,0)
;;=WOUNDS-INITIAL ENCOUNTER^38^256
;;^UTILITY(U,$J,358.4,2793,0)
;;=COMA^7^256
;;^UTILITY(U,$J,358.4,2794,0)
;;=CAUSES OF INJURY^6^256
;;^UTILITY(U,$J,358.4,2795,0)
;;=DEMENTIA^8^256
;;^UTILITY(U,$J,358.4,2796,0)
;;=LONG TERM CURRENT DRUG THERAPY^24^256
;;^UTILITY(U,$J,358.4,2797,0)
;;=NEW PATIENT^2^257
;;^UTILITY(U,$J,358.4,2798,0)
;;=ESTABLISHED PATIENT^1^257
;;^UTILITY(U,$J,358.4,2799,0)
;;=CONSULTATIONS^3^257
;;^UTILITY(U,$J,358.4,2800,0)
;;=POST OP VISIT (GLOBAL)^4^257
;;^UTILITY(U,$J,358.4,2801,0)
;;=PENIS & SCROTUM^7^258
;;^UTILITY(U,$J,358.4,2802,0)
;;=URINARY TRACT DRAINAGE & IMAGING^9^258
;;^UTILITY(U,$J,358.4,2803,0)
;;=URODYNAMICS^10^258
;;^UTILITY(U,$J,358.4,2804,0)
;;=INJ & INTRAVESICAL MEDS^4^258
;;^UTILITY(U,$J,358.4,2805,0)
;;=CYSTOURETHROSCOPY^1^258
;;^UTILITY(U,$J,358.4,2806,0)
;;=PROSTATE BIOPSY & IMAGING^8^258
;;^UTILITY(U,$J,358.4,2807,0)
;;=NURSING PROCEDURES^6^258
;;^UTILITY(U,$J,358.4,2808,0)
;;=MISCELLANEOUS^5^258
;;^UTILITY(U,$J,358.4,2809,0)
;;=IMMUNIZATION ADMIN^2^258
;;^UTILITY(U,$J,358.4,2810,0)
;;=IMMUNIZATIONS^3^258
;;^UTILITY(U,$J,358.4,2811,0)
;;=BLADDER^3^259
;;^UTILITY(U,$J,358.4,2812,0)
;;=BENIGN NEOPLASIA-KIDNEY/URETER^1^259
;;^UTILITY(U,$J,358.4,2813,0)
;;=KIDNEY/URETER^5^259
;;^UTILITY(U,$J,358.4,2814,0)
;;=MALIGNANT NEOPLASMS^6^259
;;^UTILITY(U,$J,358.4,2815,0)
;;=COMPLICATIONS^4^259
;;^UTILITY(U,$J,358.4,2816,0)
;;=NEURO UROLOGY^7^259
;;^UTILITY(U,$J,358.4,2817,0)
;;=BENIGN NEOPLASM-PENIS^2^259
;;^UTILITY(U,$J,358.4,2818,0)
;;=SEXUAL DISORDERS^11^259
;;^UTILITY(U,$J,358.4,2819,0)
;;=PENILE CONDITIONS^8^259
;;^UTILITY(U,$J,358.4,2820,0)
;;=POST OPERATIVE COMPLICATIONS^9^259
;;^UTILITY(U,$J,358.4,2821,0)
;;=PROSTATIC CONDITIONS^10^259
;;^UTILITY(U,$J,358.4,2822,0)
;;=TESTICULAR CONDITIONS^12^259
;;^UTILITY(U,$J,358.4,2823,0)
;;=URETHRAL CONDITIONS^13^259
;;^UTILITY(U,$J,358.4,2824,0)
;;=URINARY SYMPTOMS^14^259
;;^UTILITY(U,$J,358.4,2825,0)
;;=CEREBROVASCULAR ARTERIAL STUDIES^1^260
;;^UTILITY(U,$J,358.4,2826,0)
;;=EXTREMITY ARTERIAL-VENOUS STUDIES^3^260
;;^UTILITY(U,$J,358.4,2827,0)
;;=EXTREMITY VENOUS STUDIES^4^260
;;^UTILITY(U,$J,358.4,2828,0)
;;=VISCERAL/PENILE VASCULAR STUDIES^6^260
;;^UTILITY(U,$J,358.4,2829,0)
;;=EXTREMITY ARTERIAL STUDIES^2^260
;;^UTILITY(U,$J,358.4,2830,0)
;;=ULTRASOUNDS^5^260
;;^UTILITY(U,$J,358.4,2831,0)
;;=COMMON VASCULAR DX^1^261
;;^UTILITY(U,$J,358.4,2832,0)
;;=ABDOMINAL PAIN^2^261
;;^UTILITY(U,$J,358.4,2833,0)
;;=AFTERCARE POST SURGERY^3^261
;;^UTILITY(U,$J,358.4,2834,0)
;;=CARDIOVASCULAR^4^261
;;^UTILITY(U,$J,358.4,2835,0)
;;=METASTATIC CANCER SITES^5^261
;;^UTILITY(U,$J,358.4,2836,0)
;;=POST-OP COMPLICATIONS^6^261
;;^UTILITY(U,$J,358.4,2837,0)
;;=RESPIRATORY^8^261
;;^UTILITY(U,$J,358.4,2838,0)
;;=SIGNS & SYMPTOMS^9^261
;;^UTILITY(U,$J,358.4,2839,0)
;;=PRE-OP^7^261
;;^UTILITY(U,$J,358.4,2840,0)
;;=NEW PATIENT^2^262
;;^UTILITY(U,$J,358.4,2841,0)
;;=ESTABLISHED PATIENT^1^262
;;^UTILITY(U,$J,358.4,2842,0)
;;=CONSULTATIONS^3^262
;;^UTILITY(U,$J,358.4,2843,0)
;;=DEBRIDEMENT^1^263
;;^UTILITY(U,$J,358.4,2844,0)
;;=I&D/ASPIRATION^2^263
;;^UTILITY(U,$J,358.4,2845,0)
;;=UNNA BOOT^4^263
;;^UTILITY(U,$J,358.4,2846,0)
;;=PEG TUBE^3^263
;;^UTILITY(U,$J,358.4,2847,0)
;;=WOUND VAC DRESSING^6^263
;;^UTILITY(U,$J,358.4,2848,0)
;;=VASCULAR PROCEDURES^5^263
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3J5 3963 printed Oct 16, 2024@18:50:33 Page 2
IBDEI3J5 ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,2789,0)
+2 ;;=SUBSTANCE DISORDERS^35^256
+3 ;;^UTILITY(U,$J,358.4,2790,0)
+4 ;;=VARICOSE VEINS^36^256
+5 ;;^UTILITY(U,$J,358.4,2791,0)
+6 ;;=WOMEN'S HEALTH^37^256
+7 ;;^UTILITY(U,$J,358.4,2792,0)
+8 ;;=WOUNDS-INITIAL ENCOUNTER^38^256
+9 ;;^UTILITY(U,$J,358.4,2793,0)
+10 ;;=COMA^7^256
+11 ;;^UTILITY(U,$J,358.4,2794,0)
+12 ;;=CAUSES OF INJURY^6^256
+13 ;;^UTILITY(U,$J,358.4,2795,0)
+14 ;;=DEMENTIA^8^256
+15 ;;^UTILITY(U,$J,358.4,2796,0)
+16 ;;=LONG TERM CURRENT DRUG THERAPY^24^256
+17 ;;^UTILITY(U,$J,358.4,2797,0)
+18 ;;=NEW PATIENT^2^257
+19 ;;^UTILITY(U,$J,358.4,2798,0)
+20 ;;=ESTABLISHED PATIENT^1^257
+21 ;;^UTILITY(U,$J,358.4,2799,0)
+22 ;;=CONSULTATIONS^3^257
+23 ;;^UTILITY(U,$J,358.4,2800,0)
+24 ;;=POST OP VISIT (GLOBAL)^4^257
+25 ;;^UTILITY(U,$J,358.4,2801,0)
+26 ;;=PENIS & SCROTUM^7^258
+27 ;;^UTILITY(U,$J,358.4,2802,0)
+28 ;;=URINARY TRACT DRAINAGE & IMAGING^9^258
+29 ;;^UTILITY(U,$J,358.4,2803,0)
+30 ;;=URODYNAMICS^10^258
+31 ;;^UTILITY(U,$J,358.4,2804,0)
+32 ;;=INJ & INTRAVESICAL MEDS^4^258
+33 ;;^UTILITY(U,$J,358.4,2805,0)
+34 ;;=CYSTOURETHROSCOPY^1^258
+35 ;;^UTILITY(U,$J,358.4,2806,0)
+36 ;;=PROSTATE BIOPSY & IMAGING^8^258
+37 ;;^UTILITY(U,$J,358.4,2807,0)
+38 ;;=NURSING PROCEDURES^6^258
+39 ;;^UTILITY(U,$J,358.4,2808,0)
+40 ;;=MISCELLANEOUS^5^258
+41 ;;^UTILITY(U,$J,358.4,2809,0)
+42 ;;=IMMUNIZATION ADMIN^2^258
+43 ;;^UTILITY(U,$J,358.4,2810,0)
+44 ;;=IMMUNIZATIONS^3^258
+45 ;;^UTILITY(U,$J,358.4,2811,0)
+46 ;;=BLADDER^3^259
+47 ;;^UTILITY(U,$J,358.4,2812,0)
+48 ;;=BENIGN NEOPLASIA-KIDNEY/URETER^1^259
+49 ;;^UTILITY(U,$J,358.4,2813,0)
+50 ;;=KIDNEY/URETER^5^259
+51 ;;^UTILITY(U,$J,358.4,2814,0)
+52 ;;=MALIGNANT NEOPLASMS^6^259
+53 ;;^UTILITY(U,$J,358.4,2815,0)
+54 ;;=COMPLICATIONS^4^259
+55 ;;^UTILITY(U,$J,358.4,2816,0)
+56 ;;=NEURO UROLOGY^7^259
+57 ;;^UTILITY(U,$J,358.4,2817,0)
+58 ;;=BENIGN NEOPLASM-PENIS^2^259
+59 ;;^UTILITY(U,$J,358.4,2818,0)
+60 ;;=SEXUAL DISORDERS^11^259
+61 ;;^UTILITY(U,$J,358.4,2819,0)
+62 ;;=PENILE CONDITIONS^8^259
+63 ;;^UTILITY(U,$J,358.4,2820,0)
+64 ;;=POST OPERATIVE COMPLICATIONS^9^259
+65 ;;^UTILITY(U,$J,358.4,2821,0)
+66 ;;=PROSTATIC CONDITIONS^10^259
+67 ;;^UTILITY(U,$J,358.4,2822,0)
+68 ;;=TESTICULAR CONDITIONS^12^259
+69 ;;^UTILITY(U,$J,358.4,2823,0)
+70 ;;=URETHRAL CONDITIONS^13^259
+71 ;;^UTILITY(U,$J,358.4,2824,0)
+72 ;;=URINARY SYMPTOMS^14^259
+73 ;;^UTILITY(U,$J,358.4,2825,0)
+74 ;;=CEREBROVASCULAR ARTERIAL STUDIES^1^260
+75 ;;^UTILITY(U,$J,358.4,2826,0)
+76 ;;=EXTREMITY ARTERIAL-VENOUS STUDIES^3^260
+77 ;;^UTILITY(U,$J,358.4,2827,0)
+78 ;;=EXTREMITY VENOUS STUDIES^4^260
+79 ;;^UTILITY(U,$J,358.4,2828,0)
+80 ;;=VISCERAL/PENILE VASCULAR STUDIES^6^260
+81 ;;^UTILITY(U,$J,358.4,2829,0)
+82 ;;=EXTREMITY ARTERIAL STUDIES^2^260
+83 ;;^UTILITY(U,$J,358.4,2830,0)
+84 ;;=ULTRASOUNDS^5^260
+85 ;;^UTILITY(U,$J,358.4,2831,0)
+86 ;;=COMMON VASCULAR DX^1^261
+87 ;;^UTILITY(U,$J,358.4,2832,0)
+88 ;;=ABDOMINAL PAIN^2^261
+89 ;;^UTILITY(U,$J,358.4,2833,0)
+90 ;;=AFTERCARE POST SURGERY^3^261
+91 ;;^UTILITY(U,$J,358.4,2834,0)
+92 ;;=CARDIOVASCULAR^4^261
+93 ;;^UTILITY(U,$J,358.4,2835,0)
+94 ;;=METASTATIC CANCER SITES^5^261
+95 ;;^UTILITY(U,$J,358.4,2836,0)
+96 ;;=POST-OP COMPLICATIONS^6^261
+97 ;;^UTILITY(U,$J,358.4,2837,0)
+98 ;;=RESPIRATORY^8^261
+99 ;;^UTILITY(U,$J,358.4,2838,0)
+100 ;;=SIGNS & SYMPTOMS^9^261
+101 ;;^UTILITY(U,$J,358.4,2839,0)
+102 ;;=PRE-OP^7^261
+103 ;;^UTILITY(U,$J,358.4,2840,0)
+104 ;;=NEW PATIENT^2^262
+105 ;;^UTILITY(U,$J,358.4,2841,0)
+106 ;;=ESTABLISHED PATIENT^1^262
+107 ;;^UTILITY(U,$J,358.4,2842,0)
+108 ;;=CONSULTATIONS^3^262
+109 ;;^UTILITY(U,$J,358.4,2843,0)
+110 ;;=DEBRIDEMENT^1^263
+111 ;;^UTILITY(U,$J,358.4,2844,0)
+112 ;;=I&D/ASPIRATION^2^263
+113 ;;^UTILITY(U,$J,358.4,2845,0)
+114 ;;=UNNA BOOT^4^263
+115 ;;^UTILITY(U,$J,358.4,2846,0)
+116 ;;=PEG TUBE^3^263
+117 ;;^UTILITY(U,$J,358.4,2847,0)
+118 ;;=WOUND VAC DRESSING^6^263
+119 ;;^UTILITY(U,$J,358.4,2848,0)
+120 ;;=VASCULAR PROCEDURES^5^263
